Tsc2, a positional candidate gene underlying a quantitative trait locus for hepatic steatosis

Journal of Lipid Research

Volumn 53, Issue 8, 2012, Pages 1493-1501

  Wang, Chen Yu ^a   Stapleton, Donald S ^a   Schueler, Kathryn L ^a   Rabaglia, Mary E ^a   Oler, Angie T ^a   Keller, Mark P ^a   Kendziorski, Christina M ^b   Broman, Karl W ^b   Yandell, Brian S ^c   Schadt, Eric E ^d   Attie, Alan D ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c University of Wisconsin Madison   (United States)

^d ROSETTA INPHARMATICS   (United States)

Author keywords

Cell proliferation; Diabetes; Fatty acid metabolism; Genetics; Nonalcoholic fatty liver disease; Triglycerides

Indexed keywords

INSULIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TRIACYLGLYCEROL; TUBERIN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CELL PROLIFERATION; CHROMOSOME 17; FATTY LIVER; GENE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENE LOCUS; GENETIC DIFFERENCE; LIPID LIVER LEVEL; LIPOGENESIS; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN METABOLISM; QUANTITATIVE TRAIT LOCUS; QUANTITATIVE TRAIT LOCUS MAPPING; SINGLE NUCLEOTIDE POLYMORPHISM; SREBP1C GENE; TSC2 GENE;

ALLELES; ANIMALS; CELL PROLIFERATION; CHROMOSOMES, MAMMALIAN; FATTY LIVER; GENE EXPRESSION REGULATION; INSULIN-SECRETING CELLS; LIPOGENESIS; LIVER; MICE; QUANTITATIVE TRAIT LOCI; SPECIES SPECIFICITY; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TRIGLYCERIDES; TUMOR SUPPRESSOR PROTEINS;

EID: 84863804630     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M025239     Document Type: Article

References (62)

1. Schwimmer, J. B., R. Deutsch, T. Kahen, J. E. Lavine, C. Stanley, and C. Behling. 2006. Prevalence of fatty liver in children and adolescents. Pediatrics. 118: 1388-1393. (Pubitemid 46393782)
2. Adams, L. A., and P. Angulo. 2005. Recent concepts in nonalcoholic fatty liver disease. Diabet. Med. 22: 1129-1133. (Pubitemid 41224168)
3. Adams, L. A., P. Angulo, and K. D. Lindor. 2005. Nonalcoholic fatty liver disease. Can. Med. Assoc. J. 172: 899-905. (Pubitemid 40543601)
4. Adams, L. A., J. F. Lymp, J. St Sauver, S. O. Sanderson, K. D. Lindor, A. Feldstein, and P. Angulo. 2005. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 129: 113-121. (Pubitemid 41002048)
5. McCullough, A. J. 2004. The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. Clin. Liver Dis. 8: 521-533 (viii.). (Pubitemid 39141140)
6. Browning, J. D., L. S. Szczepaniak, R. Dobbins, P. Nuremberg, J. D. Horton, J. C. Cohen, S. M. Grundy, and H. H. Hobbs. 2004. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 40: 1387-1395. (Pubitemid 39657013)
7. Musso, G., R. Gambino, F. De Michieli, M. Durazzo, G. Pagano, and M. Cassader. 2008. Adiponectin gene polymorphisms modulate acute adiponectin response to dietary fat: Possible pathogenetic role in NASH. Hepatology. 47: 1167-1177. (Pubitemid 351547903)
8. Romeo, S., J. Kozlitina, C. Xing, A. Pertsemlidis, D. Cox, L. A. Pennacchio, E. Boerwinkle, J. C. Cohen, and H. H. Hobbs. 2008. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat. Genet. 40: 1461-1465.
9. Sookoian, S., G. Castano, C. Gemma, T. F. Gianotti, and C. J. Pirola. 2007. Common genetic variations in CLOCK transcription factor are associated with nonalcoholic fatty liver disease. World J. Gastroenterol. 13: 4242-4248. (Pubitemid 47377164)
10. Yoneda, M., K. Hotta, Y. Nozaki, H. Endo, T. Uchiyama, H. Mawatari, H. Iida, S. Kato, K. Hosono, K. Fujita, et al. 2008. Association between PPARGC1A polymorphisms and the occurrence of nonalcoholic fatty liver disease (NAFLD). BMC Gastroenterol. 8: 27.
11. Day, C. P. 2006. Non-alcoholic fatty liver disease: current concepts and management strategies. Clin. Med. 6: 19-25.
12. Bilger, A., L. M. Bennett, R. A. Carabeo, T. A. Chiaverotti, C. Dvorak, K. M. Liss, S. A. Schadewald, H. C. Pitot, and N. R. Drinkwater. 2004. A potent modifier of liver cancer risk on distal mouse chromosome 1: linkage analysis and characterization of congenic lines. Genetics. 167: 859-866. (Pubitemid 38931870)
13. Bilger, A., R. Sullivan, A. J. Prunuske, L. Clipson, N. R. Drinkwater, and W. F. Dove. 2008. Widespread hyperplasia induced by transgenic TGFalpha in ApcMin mice is associated with only regional effects on tumorigenesis. Carcinogenesis. 29: 1825-1830.
14. Clee, S. M., and A. D. Attie. 2007. The genetic landscape of type 2 diabetes in mice. Endocr. Rev. 28: 48-83 (PubMed). (Pubitemid 46220850)
15. Clee, S. M., B. S. Yandell, K. M. Schueler, M. E. Rabaglia, O. C. Richards, S. M. Raines, E. A. Kabara, D. M. Klass, E. T. Mui, D. S. Stapleton, et al. 2006. Positional cloning of Sorcs1, a type 2 diabetes quantitative trait locus. Nat. Genet. 38: 688-693. (Pubitemid 43927312)
16. Kotb, M., N. Fathey, R. Aziz, S. Rowe, R. W. Williams, and L. Lu. 2008. Unbiased forward genetics and systems biology approaches to understanding how gene-environment interactions work to predict susceptibility and outcomes of infections. Novartis Found. Symp. 293: 156-165; discussion 165-157, 181-153.
17. Marquis, J. F., and P. Gros. 2008. Genetic analysis of resistance to infections in mice: A/J meets C57BL/6J. Curr. Top. Microbiol. Immunol. 321: 27-57.
18. Reddy, J. K., and T. Hashimoto. 2001. Peroxisomal beta-oxidation and peroxisome proliferator-activated receptor alpha: an adaptive metabolic system. Annu. Rev. Nutr. 21: 193-230. (Pubitemid 32695270)
19. Smith, S. J., S. Cases, D. R. Jensen, H. C. Chen, E. Sande, B. Tow, D. A. Sanan, J. Raber, R. H. Eckel, and R. V. Farese, Jr. 2000. Obesity resistance and multiple mechanisms of triglyceride synthesis in mice lacking Dgat. Nat. Genet. 25: 87-90. (Pubitemid 30257043)
20. Tolwani, R. J., D. A. Hamm, L. Tian, J. D. Sharer, J. Vockley, P. Rinaldo, D. Matern, T. R. Schoeb, and P. A. Wood. 2005. Medium-chain acyl-CoA dehydrogenase deficiency in gene-targeted mice. PLoS Genet. 1: e23.
21. Yu, X. X., S. F. Murray, S. K. Pandey, S. L. Booten, D. Bao, X. Z. Song, S. Kelly, S. Chen, R. McKay, B. P. Monia, et al. 2005. Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice. Hepatology. 42: 362-371. (Pubitemid 41061089)
22. Chalasani, N., X. Guo, R. Loomba, M. O. Goodarzi, T. Haritunians, S. Kwon, J. Cui, K. D. Taylor, L. Wilson, O. W. Cummings, et al. 2010. Genome-wide association study identifies variants associated with histologic features of nonalcoholic Fatty liver disease. Gastroenterology. 139: 1567-1576, e1561-1566.
23. Keller, M. P., Y. Choi, P. Wang, D. B. Davis, M. E. Rabaglia, A. T. Oler, D. S. Stapleton, C. Argmann, K. L. Schueler, S. Edwards, et al. 2008. A gene expression network model of type 2 diabetes links cell cycle regulation in islets with diabetes susceptibility. Genome Res. 18: 706-716. (Pubitemid 351645061)
24. Bhatnagar, S., A. T. Oler, M. E. Rabaglia, D. S. Stapleton, K. L. Schueler, N. A. Truchan, S. L. Worzella, J. P. Stoehr, S. M. Clee, B. S. Yandell, et al. 2011. Positional cloning of a type 2 diabetes quantitative trait locus; tomosyn-2, a negative regulator of insulin secretion. PLoS Genet. 7: e1002323.
25. Lan, H., M. E. Rabaglia, J. P. Stoehr, S. T. Nadler, K. L. Schueler, F. Zou, B. S. Yandell, and A. D. Attie. 2003. Gene expression profiles of nondiabetic and diabetic obese mice suggest a role of hepatic lipogenic capacity in diabetes susceptibility. Diabetes. 52: 688-700. (Pubitemid 36323576)
26. Broman, K. W., H. Wu, S. Sen, and G. A. Churchill. 2003. R/qtl: QTL mapping in experimental crosses. Bioinformatics. 19: 889-890. (Pubitemid 36582406)
27. Churchill, G. A., and R. W. Doerge. 1994. Empirical threshold values for quantitative trait mapping. Genetics. 138: 963-971 (PubMed). (Pubitemid 24337818)
28. Manichaikul, A., J. Dupuis, S. Sen, and K. W. Broman. 2006. Poor performance of bootstrap confidence intervals for the location of a quantitative trait locus. Genetics. 174: 481-489. (Pubitemid 44427688)
29. Benvenuto, G., S. Li, S. J. Brown, R. Braverman, W. C. Vass, J. P. Cheadle, D. J. Halley, J. R. Sampson, R. Wienecke, and J. E. DeClue. 2000. The tuberous sclerosis-1 (TSC1) gene product hamartin suppresses cell growth and augments the expression of the TSC2 product tuberin by inhibiting its ubiquitination. Oncogene. 19: 6306-6316. (Pubitemid 32641844)
30. Zhang, Y., X. Gao, L. J. Saucedo, B. Ru, B. A. Edgar, and D. Pan. 2003. Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins. Nat. Cell Biol. 5: 578-581. (Pubitemid 36781094)
31. Inoki, K., Y. Li, T. Xu, and K. L. Guan. 2003. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev. 17: 1829-1834. (Pubitemid 36944560)
32. Tee, A. R., J. Blenis, and C. G. Proud. 2005. Analysis of mTOR signaling by the small G-proteins, Rheb and RhebL1. FEBS Lett. 579: 4763-4768. (Pubitemid 41218660)
33. Tabancay, A. P., Jr., C. L. Gau, I. M. Machado, E. J. Uhlmann, D. H. Gutmann, L. Guo, and F. Tamanoi. 2003. Identification of dominant negative mutants of Rheb GTPase and their use to implicate the involvement of human Rheb in the activation of p70S6K. J. Biol. Chem. 278: 39921-39930. (Pubitemid 37248556)
34. Onda, H., A. Lueck, P. W. Marks, H. B. Warren, and D. J. Kwiatkowski. 1999. Tsc2(+/-) mice develop tumors in multiple sites that express gelsolin and are influenced by genetic background. J. Clin. Invest. 104: 687-695. (Pubitemid 29536354)
35. Rachdi, L., N. Balcazar, F. Osorio-Duque, L. Elghazi, A. Weiss, A. Gould, K. J. Chang-Chen, M. J. Gambello, and E. Bernal-Mizrachi. 2008. Disruption of Tsc2 in pancreatic beta cells induces beta cell mass expansion and improved glucose tolerance in a TORC1-dependent manner. Proc. Natl. Acad. Sci. USA. 105: 9250-9255.
36. Bartolome, A., C. Guillen, and M. Benito. 2010. Role of the TSC1-TSC2 complex in the integration of insulin and glucose signaling involved in pancreatic beta-cell proliferation. Endocrinology. 151: 3084-3094.
37. Chong-Kopera, H., K. Inoki, Y. Li, T. Zhu, F. R. Garcia-Gonzalo, J. L. Rosa, and K. L. Guan. 2006. TSC1 stabilizes TSC2 by inhibiting the interaction between TSC2 and the HERC1 ubiquitin ligase. J. Biol. Chem. 281: 8313-8316. (Pubitemid 43847930)
38. Inoki, K., Y. Li, T. Zhu, J. Wu, and K. L. Guan. 2002. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat. Cell Biol. 4: 648-657. (Pubitemid 34993700)
39. Kwiatkowski, D. J. 2003. Rhebbing up mTOR: new insights on TSC1 and TSC2, and the pathogenesis of tuberous sclerosis. Cancer Biol. Ther. 2: 471-476.
40. Kwiatkowski, D. J. 2003. Tuberous sclerosis: from tubers to mTOR. Ann. Hum. Genet. 67: 87-96 (PubMed). (Pubitemid 38312854)
41. Nellist, M., O. Sancak, M. A. Goedbloed, C. Rohe, D. van Netten, K. Mayer, A. Tucker-Williams, A. M. van den Ouweland, and D. J. Halley. 2005. Distinct effects of single amino-acid changes to tuberin on the function of the tuberin-hamartin complex. Eur. J. Hum. Genet. 13: 59-68.
42. Nellist, M., O. Sancak, M. A. Goedbloed, M. van Veghel-Plandsoen, A. Maat-Kievit, D. Lindhout, B. H. Eussen, A. de Klein, D. J. Halley, and A. M. van den Ouweland. 2005. Large deletion at the TSC1 locus in a family with tuberous sclerosis complex. Genet. Test. 9: 226-230. (Pubitemid 41507755)
43. Hodges, A. K., S. Li, J. Maynard, L. Parry, R. Braverman, J. P. Cheadle, J. E. DeClue, and J. R. Sampson. 2001. Pathological mutations in TSC1 and TSC2 disrupt the interaction between hamartin and tuberin. Hum. Mol. Genet. 10: 2899-2905. (Pubitemid 34030921)
44. Kandt, R. S., J. L. Haines, M. Smith, H. Northrup, R. J. Gardner, M. P. Short, K. Dumars, E. S. Roach, S. Steingold, S. Wall, et al. 1992. Linkage of an important gene locus for tuberous sclerosis to a chromosome 16 marker for polycystic kidney disease. Nat. Genet. 2: 37-41.
45. van Slegtenhorst, M., R. de Hoogt, C. Hermans, M. Nellist, B. Janssen, S. Verhoef, D. Lindhout, A. van den Ouweland, D. Halley, J. Young, et al. 1997. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science. 277: 805-808. (Pubitemid 27366729)
46. Huang, J., and B. D. Manning. 2008. The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. Biochem. J. 412: 179-190. (Pubitemid 351758225)
47. Inoki, K., M. N. Corradetti, and K. L. Guan. 2005. Dysregulation of the TSC-mTOR pathway in human disease. Nat. Genet. 37: 19-24. (Pubitemid 40070934)
48. Zhang, H. H., J. Huang, K. Duvel, B. Boback, S. Wu, R. M. Squillace, C. L. Wu, and B. D. Manning. 2009. Insulin stimulates adipogenesis through the Akt-TSC2-mTORC1 pathway. PLoS ONE. 4: e6189.
49. Duvel, K., J. L. Yecies, S. Menon, P. Raman, A. I. Lipovsky, A. L. Souza, E. Triantafellow, Q. Ma, R. Gorski, S. Cleaver, et al. 2010. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol. Cell. 39: 171-183.
50. Li, S., M. S. Brown, and J. L. Goldstein. 2010. Bifurcation of insulin signaling pathway in rat liver: mTORC1 required for stimulation of lipogenesis, but not inhibition of gluconeogenesis. Proc. Natl. Acad. Sci. USA. 107: 3441-3446.
51. Chakrabarti, P., T. English, J. Shi, C. M. Smas, and K. V. Kandror. 2010. Mammalian target of rapamycin complex 1 suppresses lipolysis, stimulates lipogenesis, and promotes fat storage. Diabetes. 59: 775-781.
52. Peterson, T. R., S. S. Sengupta, T. E. Harris, A. E. Carmack, S. A. Kang, E. Balderas, D. A. Guertin, K. L. Madden, A. E. Carpenter, B. N. Finck, et al. 2011. mTOR complex 1 regulates lipin 1 localization to control the SREBP pathway. Cell. 146: 408-420.
53. Manning, B. D. 2004. Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis. J. Cell Biol. 167: 399-403. (Pubitemid 39489047)
54. Sancak, Y., C. C. Thoreen, T. R. Peterson, R. A. Lindquist, S. A. Kang, E. Spooner, S. A. Carr, and D. M. Sabatini. 2007. PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol. Cell. 25: 903-915. (Pubitemid 46436534)
55. Yecies, J. L., H. H. Zhang, S. Menon, S. Liu, D. Yecies, A. I. Lipovsky, C. Gorgun, D. J. Kwiatkowski, G. S. Hotamisligil, C. H. Lee, et al. 2011. Akt stimulates hepatic SREBP1c and lipogenesis through parallel mTORC1-dependent and independent pathways. Cell Metab. 14: 21-32.
56. Wan, M., K. F. Leavens, D. Saleh, R. M. Easton, D. A. Guertin, T. R. Peterson, K. H. Kaestner, D. M. Sabatini, and M. J. Birnbaum. 2011. Postprandial hepatic lipid metabolism requires signaling through Akt2 independent of the transcription factors FoxA2, FoxO1, and SREBP1c. Cell Metab. 14: 516-527.
57. Reiter, A. K., D. R. Bolster, S. J. Crozier, S. R. Kimball, and L. S. Jefferson. 2005. Repression of protein synthesis and mTOR signaling in rat liver mediated by the AMPK activator aminoimidazole carboxamide ribonucleoside. Am. J. Physiol. Endocrinol. Metab. 288: E980-E988. (Pubitemid 40547893)
58. Reiter, A. K., D. R. Bolster, S. J. Crozier, S. R. Kimball, and L. S. Jefferson. 2008. AMPK represses TOP mRNA translation but not global protein synthesis in liver. Biochem. Biophys. Res. Commun. 374: 345-350.
59. Hill-Baskin, A. E., M. M. Markiewski, D. A. Buchner, H. Shao, D. DeSantis, G. Hsiao, S. Subramaniam, N. A. Berger, C. Croniger, J. D. Lambris, et al. 2009. Diet-induced hepatocellular carcinoma in genetically predisposed mice. Hum. Mol. Genet. 18: 2975-2988.
60. Yang, S., H. Z. Lin, J. Hwang, V. P. Chacko, and A. M. Diehl. 2001. Hepatic hyperplasia in noncirrhotic fatty livers: is obesity-related hepatic steatosis a premalignant condition? Cancer Res. 61: 5016-5023. (Pubitemid 32681529)
61. Bugianesi, E. 2007. Non-alcoholic steatohepatitis and cancer. Clin. Liver Dis. 11: 191-207 (x-xi.). (Pubitemid 46829971)
62. Finlay, G. A., A. J. Malhowski, K. Polizzi, I. Malinowska-Kolodziej, and D. J. Kwiatkowski. 2009. Renal and liver tumors in Tsc2(+/-) mice, a model of tuberous sclerosis complex, do not respond to treatment with atorvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Mol. Cancer Ther. 8: 1799-1807.